Although the Phase III trial of Allovectin-7 failed to meet key endpoints, the success of its Phase I/Phase II trials and related basic studies still demonstrates that B2M gene delivery can address the problems its mutation poses to T-cell-based tumor immunity. The gene discussed is B2M; the disease is neoplasm.